BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)(BVXV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BVXV BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)

Pre-Market Trading 11-25 04:57:45 EST

1.36

+0.00

0.00%

High1.36	Low1.36	Vol0.00
Open1.36	D1 Closing1.36	Amplitude0.00%
Mkt Cap4.97M	Tradable Cap3.72M	Total Shares3.65M
T/O30.28K	T/O Rate0.00%	Tradable Shares2.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BVXV","market":"US","secType":"STK","nameCN":"BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)","latestPrice":1.36,"timestamp":1694030400000,"preClose":1.36,"halted":8,"volume":0,"delay":0,"floatShares":2733209,"shares":3651926,"eps":-3.076138,"marketStatus":"Pre-Market Trading","change":0,"latestTime":"11-25 04:57:45 EST","open":1.36,"high":1.36,"low":1.36,"amount":30276.397876,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.076138,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732545000000},"marketStatusCode":1,"symbolChange":{"newSymbol":"SCNI","executeDate":"2023-09-07"},"adr":0,"adrRate":400,"listingDate":1431403200000,"exchange":"NASDAQ","adjPreClose":1.36,"volumeRatio":0},"requestUrl":"/m/hq/s/BVXV/wiki","defaultTab":"wiki","newsList":[{"id":"2372879695","title":"Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2372879695","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2372879695?lang=en_us&edition=fundamental","pubTime":"2023-10-04 19:30","pubTimestamp":1696419000,"startTime":"0","endTime":"0","summary":"Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trials. JERUSALEM, Oct. 04, 2023  -- via IBN – Scinai Immunotherapeutics Ltd.  today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place October 24 to 26.Several members of Scinai’s executive leadership team will be available to meet with potential partners and clients of the company’s end-to-end biologics CDMO service. Scinai’s booth is located in Hall 8.1, Booth 11.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tDr6pQVC9Xs7dvDgrkUDyQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d27c58a11780bc17899436a2381bcd87","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tDr6pQVC9Xs7dvDgrkUDyQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d27c58a11780bc17899436a2381bcd87"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scinai-immunotherapeutics-showcase-end-end-113000590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","CDMO","BK4207","BK4535","IE00B0JY6M65.USD","LU0251143458.SGD","BK4585","LU0066902890.USD","SG9999004220.SGD","IE00B7N09G41.SGD","BVXV","BK4548","BK4523","IE00BYTNYM70.SGD","BK4007","BK4139","IBN","CPHI","SCNI"],"gpt_icon":0},{"id":"2368187294","title":"Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2368187294","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2368187294?lang=en_us&edition=fundamental","pubTime":"2023-09-20 04:05","pubTimestamp":1695153900,"startTime":"0","endTime":"0","summary":"JERUSALEM, Sept. 19, 2023  -- via IBN – Scinai Immunotherapeutics Ltd. , a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 1,146,552 of the Company’s American Depositary Shares  , each ADS representing four hundred  ordinary shares, at a purchase price of $1.16 per ADS . In addition, in a concurrent private placement, the Company has issued unregistered warrants to purchase up to 1,146,552 ADSs representing ordinary shares. The warrants have an exercise price of $1.16 per ADS and are immediately exercisable upon issuance for a period of five and one-half years.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tDr6pQVC9Xs7dvDgrkUDyQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d27c58a11780bc17899436a2381bcd87","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tDr6pQVC9Xs7dvDgrkUDyQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d27c58a11780bc17899436a2381bcd87"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scinai-immunotherapeutics-announces-closing-1-200500590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4207","BK4523","LU0251143458.SGD","BK4585","BVXV","IE00B0JY6M65.USD","BK4588","IE00BYTNYM70.SGD","BK4548","LU0066902890.USD","IBN","SCNI","SG9999004220.SGD","BK4535","BK4007","IE00B7N09G41.SGD"],"gpt_icon":0},{"id":"2365869010","title":"BC Study Uncovers Cause of Four Major Pediatric Allergies","url":"https://stock-news.laohu8.com/highlight/detail?id=2365869010","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2365869010?lang=en_us&edition=fundamental","pubTime":"2023-09-08 03:35","pubTimestamp":1694115300,"startTime":"0","endTime":"0","summary":"New research by scientists from the University of British Columbia  and British Columbia Children’s Hospital has revealed that four major childhood allergies may arise from a common factor. The Centers for Disease Control and Prevention  estimates that close to one in five children suffer from seasonal allergies, with 10.8% living with eczema and 5%–8% suffering from food allergies.These allergies typically occur due to factors such as outdoor and indoor triggers, irritants including perfumes and cigarette smoke, and…BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22138821","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["UBC","BK4190","BK4007","BVXV","CDC","BC"],"gpt_icon":0},{"id":"2364678648","title":"BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs","url":"https://stock-news.laohu8.com/highlight/detail?id=2364678648","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2364678648?lang=en_us&edition=fundamental","pubTime":"2023-09-02 03:15","pubTimestamp":1693595700,"startTime":"0","endTime":"0","summary":"BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody  pipeline. For more information, visit the company’s website at www.BiondVax.com.BioMedWire  is a specialized communications platform with a focus on the latest developments in the Biotechnology , Biomedica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22120052","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4534","LU2491050071.SGD","SG9999018865.SGD","LU0689472784.USD","SGXZ81514606.USD","LU2237443978.SGD","LU1267930730.SGD","LU0417517546.SGD","BK4007","LU2491049909.HKD","LU0289739699.SGD","LU0943347566.SGD","BK4533","LU0820561909.HKD","SCNI","LU2237438978.USD","LU2237443382.USD","IE0009355771.USD","LU1551013342.USD","SGXZ99366536.SGD","SGXZ51526630.SGD","LU1551013425.SGD","LU1712237335.SGD","LLY","BK4585","BK4581","LU2237443549.SGD","LU1064131342.USD","LU0320765059.SGD","SG9999017495.SGD","LU2491050154.USD","SG9999013999.USD","LU2237443622.USD","SG9999014898.SGD","BK4588","DICE","IE0002141913.USD","BVXV","LU0820561818.USD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1814569148.SGD","LU0672654240.SGD","SG9999014914.USD","LU1623119135.USD","GB00BDT5M118.USD","LU1023059063.AUD","SG9999014906.USD","IE00B2B36J28.USD","LU0256863811.USD","LU0640476718.USD"],"gpt_icon":0},{"id":"2364421410","title":"Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes","url":"https://stock-news.laohu8.com/highlight/detail?id=2364421410","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2364421410?lang=en_us&edition=fundamental","pubTime":"2023-09-01 01:55","pubTimestamp":1693504500,"startTime":"0","endTime":"0","summary":"A group of infectious disease experts from several American Army institutions has been deployed to analyze mosquitoes after Maryland recently confirmed its first nontravel-connected malaria case in more than 40 years. Experts from the Walter Reed Army Institute of Research , the Smithsonian Institution and the U.S. Army’s First Area Medical Laboratory have teamed up to understand the recent case and combat malaria’s potential reemergence within the U.S.Scientists from the Aberdeen Proving Ground-stationed First Area Medical Laboratory will be deployed to the 44th Medical Brigade in…To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22114536","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4007","IE00B7N09G41.SGD","IE00BYTNYM70.SGD","SCNI","BVXV","SG9999004220.SGD","BK4207","BK4585","BK4548","LU0251143458.SGD","BK4523","IBN","IE00B0JY6M65.USD","BK4588","LU0066902890.USD","BK4535"],"gpt_icon":0},{"id":"2363170833","title":"England Sees Soaring Numbers of Hospitalizations for Severe Allergies","url":"https://stock-news.laohu8.com/highlight/detail?id=2363170833","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2363170833?lang=en_us&edition=fundamental","pubTime":"2023-08-29 00:35","pubTimestamp":1693240500,"startTime":"0","endTime":"0","summary":"A leading national patient United Kingdom charity is concerned with the “hugely worrying” rise of allergy-related hospitalizations in England. Dangerous allergic reactions in the UK have risen in recent years and now average around 25,000 NHS hospital stays every year. According to health officials, the rate of allergy reactions in the country has grown by more than two times over the past two decades.Allergy UK posits that the increase in allergy admission rates is due to the influx of a wide variety of foods from around the globe coupled with a…To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22096129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4548","BVXV","IE00BYTNYM70.SGD","BK4585","BK4588","IE00B0JY6M65.USD","IE00B7N09G41.SGD","BK4535","LU0251143458.SGD","BK4523","IBN","BK4207","BK4007","LU0066902890.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2362905594","title":"BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17","url":"https://stock-news.laohu8.com/highlight/detail?id=2362905594","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2362905594?lang=en_us&edition=fundamental","pubTime":"2023-08-26 02:30","pubTimestamp":1692988200,"startTime":"0","endTime":"0","summary":"BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody  pipeline. For more information, visit the company’s website at www.BiondVax.com.BioMedWire  is an information service that provides  access to our news aggregation and syndication servers,  BioMedNewsBreaks that summarize corporate news and information,  enhanced press release services,  social media distribution and optimization services, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22090380","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["LU0128525689.USD","BVXV","BK4532","LU1267930227.SGD","LU1244550577.SGD","FAST","LU0310800965.SGD","BK4104","LU0052756011.USD","LU0823411888.USD","BK4588","TGT","BK4567","LU1244550494.USD","BK4007","BK4585","BK4533","LU1244550221.USD","BK4504","BK4114","BK4155"],"gpt_icon":0},{"id":"2361970696","title":"How Allergy Sufferers Can Benefit from Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2361970696","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2361970696?lang=en_us&edition=fundamental","pubTime":"2023-08-23 04:10","pubTimestamp":1692735000,"startTime":"0","endTime":"0","summary":"The Centers for Disease Control and Prevention  estimates that close to one in three adults and more than one in every four children in America have a food allergy, seasonal allergy or eczema. Close to 6% of children and adults in the country have a food allergy and 25.7% of U.S. adults have a seasonal allergy, 7.3% have eczema, and 6.2% report having a food allergy.Common allergy treatment approaches include medications to minimize immune system reaction and alleviate symptoms, epinephrine in emergencies and…To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22075799","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["IE00BYTNYM70.SGD","BK4588","BK4585","IE00B7N09G41.SGD","SG9999004220.SGD","BK4207","BVXV","IBN","IE00B0JY6M65.USD","LU0066902890.USD","BK4548","BK4535","CDC","BK4007","BK4523","LU0251143458.SGD"],"gpt_icon":0},{"id":"2360581018","title":"Analyzing Link Between Hormonal Contraceptives, Autoimmunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2360581018","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2360581018?lang=en_us&edition=fundamental","pubTime":"2023-08-19 01:10","pubTimestamp":1692378600,"startTime":"0","endTime":"0","summary":"Autoimmune diseases occur when the immune system mistakes healthy tissues for harmful bacteria, viruses, or infections and starts to attack the body. Referred to as autoimmunity, this phenomenon causes significant damage to healthy tissues and results in more than 100 autoimmune conditions.Data has consistently shown that women are four times more likely to develop autoimmune diseases compared to…To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22064669","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["LU0066902890.USD","BK4588","BK4548","BK4523","IE00BYTNYM70.SGD","LU0251143458.SGD","BK4207","BK4585","IBN","IE00B0JY6M65.USD","BK4535","IE00B7N09G41.SGD","BK4007","SG9999004220.SGD","BVXV"],"gpt_icon":0},{"id":"2360586964","title":"BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2360586964","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2360586964?lang=en_us&edition=fundamental","pubTime":"2023-08-18 23:25","pubTimestamp":1692372300,"startTime":"0","endTime":"0","summary":"Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs. BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature. The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23%. Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies  and nanosized antibodies , therapeutic options that address diseases in ways other therapies cannot. Several companies are penetrating the market and a compelling comparison can be made between two – one supporting mAbs and the other NanoAbs. Both companies share similar objectives and stages of development.BiondVax","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22064125","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BVXV","BK4548","IE00BYTNYM70.SGD","LU0251143458.SGD","BK4585","LU0066902890.USD","IBN","IE00B7N09G41.SGD","BK4523","BK4007","IE00B0JY6M65.USD","BK4535","BK4207","BK4588","SG9999004220.SGD"],"gpt_icon":0},{"id":"2360380433","title":"BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2360380433","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2360380433?lang=en_us&edition=fundamental","pubTime":"2023-08-17 00:15","pubTimestamp":1692202500,"startTime":"0","endTime":"0","summary":"BiondVax Pharmaceuticals , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good Things Coming” and gave BVXV a Buy rating. The research report noted that BiondVax has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies, called NanoAbs, targeting Interleukin-17 , specifically for the treatment of psoriasis and psoriatic arthritis. The agreement is with the Max Planck Society and the University Medical Center Gottingen  and is part of an ongoing collaboration BVXV has going with those two entities. According to the report, Max Planck and UMC Gottingen have already generated 11 potential therapeutic candidates. The report noted that the next step for BiondVax is to identify the best two or three of the potential candidates and be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22054615","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BVXV","BK4007"],"gpt_icon":0},{"id":"2359830676","title":"BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2359830676","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2359830676?lang=en_us&edition=fundamental","pubTime":"2023-08-15 01:15","pubTimestamp":1692033300,"startTime":"0","endTime":"0","summary":"Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies. The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030. The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030. The nanobody market was valued $237.1 million in 2021 and is expected reach a value of $1.07 billion by 2028. BiondVax is uniquely positioned to rapidly advance from R&D towards commercialization. The biologics market, which is comprised of any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources, was valued at $366.5 billion in 2021 and is expected to grow at a CAGR of 7.15%, resulting in a value of $719.94 billion by 2030. The introduction of targeted…","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22040711","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4207","LU0251143458.SGD","BVXV","IE00B0JY6M65.USD","LU0066902890.USD","IBN","BK4007","BK4585","SG9999004220.SGD","BK4535","BK4523","BK4548","IE00B7N09G41.SGD","IE00BYTNYM70.SGD","BK4588"],"gpt_icon":0},{"id":"2358067352","title":"BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2358067352","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2358067352?lang=en_us&edition=fundamental","pubTime":"2023-08-12 02:45","pubTimestamp":1691779500,"startTime":"0","endTime":"0","summary":"BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody  pipeline. For more information about the company, please visit www.BiondVax.com. BioMedWire  is an information service that provides  access to our news aggregation and syndication servers,  BioMedNewsBreaks that summarize corporate news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22033644","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BVXV","BK4007"],"gpt_icon":0},{"id":"2358052468","title":"BiondVax Pharmaceuticals Q2 EPS $(0.003) Up From $(2.00) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2358052468","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2358052468?lang=en_us&edition=fundamental","pubTime":"2023-08-11 21:02","pubTimestamp":1691758939,"startTime":"0","endTime":"0","summary":"BiondVax Pharmaceuticals (NASDAQ:BVXV) reported quarterly losses of $(0.00) per share. This is a 99.85 percent increase over losses of $(2.00) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/23/08/33747969/biondvax-pharmaceuticals-q2-eps-0-003-up-from-2-00-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BVXV"],"gpt_icon":0},{"id":"2358905289","title":"Press Release: BiondVax Reports Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2358905289","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2358905289?lang=en_us&edition=fundamental","pubTime":"2023-08-11 21:00","pubTimestamp":1691758800,"startTime":"0","endTime":"0","summary":"JERUSALEM, Aug. 11, 2023  -- via IBN - BiondVax Pharmaceuticals Ltd. , a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update.-- R&D expenses for the three months ended June 30, 2023, amounted to $1.45. million compared with $1.97 million for the three months ended June 30,-- Marketing, general and administrative expenses for the three months ended. June 30, 2023, amounted to $1.14 million compared with $1.29 million for. amounted to $2.56 million compared with $3.26 million for the three. -- Financial  income for the three months ended June 30, 2023,amounted to $1.16 million loss compared with $0.28 million income for the. -- Net loss for the three months ended June 30, 2023, amounted to $3.76","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BVXV","BK4007"],"gpt_icon":0},{"id":"2358637750","title":"How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota","url":"https://stock-news.laohu8.com/highlight/detail?id=2358637750","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2358637750?lang=en_us&edition=fundamental","pubTime":"2023-08-10 01:05","pubTimestamp":1691600700,"startTime":"0","endTime":"0","summary":"Immunotherapy presents a relatively new means of treating cancer cells that leverages a patient’s own immune system. Rather than introduce drugs to attack and kill cancer cells, immunotherapy is more concerned with training the immune system to become more effective at finding and killing cancer cells.This treatment is more effective against specific types of cancers, including tumors that don’t respond to conventional treatments, recurring cancer and…To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22019843","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BVXV","IE00B0JY6M65.USD","BK4585","LU0251143458.SGD","IE00B7N09G41.SGD","BK4588","IE00BYTNYM70.SGD","LU0066902890.USD","BK4523","BK4535","SG9999004220.SGD","BK4007","IBN","BK4548","BK4207"],"gpt_icon":0},{"id":"2356812474","title":"Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset","url":"https://stock-news.laohu8.com/highlight/detail?id=2356812474","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2356812474?lang=en_us&edition=fundamental","pubTime":"2023-08-04 02:00","pubTimestamp":1691085600,"startTime":"0","endTime":"0","summary":"Researchers from the Murdoch Children’s Research Institute  in Australia have discovered a link between food allergy in infants and asthma with diminished lung function in later childhood years. The researchers believe their findings may help physicians be more vigilant regarding the respiratory health of young children dealing with food allergies.Stanford Medicine Children’s Health estimates that around 5% of children below the age of five suffer from food allergies, with the…To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21993612","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4207","LU0251143458.SGD","BVXV","IE00B0JY6M65.USD","LU0066902890.USD","MCRI","IBN","BK4007","BK4585","BK4150","SG9999004220.SGD","BK4535","BK4523","BK4548","IE00B7N09G41.SGD","IE00BYTNYM70.SGD","BK4588"],"gpt_icon":0},{"id":"2356135360","title":"Nasdaq grants BiondVax extension to regain compliance with listing rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2356135360","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2356135360?lang=en_us&edition=fundamental","pubTime":"2023-08-02 19:53","pubTimestamp":1690977204,"startTime":"0","endTime":"0","summary":"BiondVax Pharmaceuticals  said Nasdaq provided an extension until October end as it reviewed the biotechnology company's multi-faceted plan to regain compliance with Nasdaq’s listing rules. Previously BiondVax received a deficiency letter Nasdaq notifying the company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. BiondVax has provided Nasdaq with its business plan, which includes the pursuit of several non-dilutive grants, potential capital-raising transactions, and development of the company’s new CDMO business.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3994988-nasdaq-grants-biondvax-extension-to-regain-compliance-listing-rules","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BVXV","SQQQ","QLD",".IXIC","TQQQ","QID","PSQ","NQmain","QQQ","BK4007","MNQmain"],"gpt_icon":0},{"id":"2355589586","title":"BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2355589586","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2355589586?lang=en_us&edition=fundamental","pubTime":"2023-07-29 01:00","pubTimestamp":1690563600,"startTime":"0","endTime":"0","summary":"BiondVax  is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody  therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine, which is implicated in several diseases] for the treatment of psoriasis, where the market for therapeutics is expected to reach $44 billion by 2031,” reads a recent article. “The company’s plan for the IL-17 nanobody also includes addressing diseases like hidradenitis suppurativa , psoriatic arthritis and other large markets. BiondVax intends to use IL-17 in mild-to-moderate psoriasis patients, which comprise a higher number of patients compared to the smaller segment of severe patien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21964033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["LU1244550494.USD","LU0052756011.USD","BK4533","LU1267930227.SGD","LU0823411888.USD","BK4114","BK4532","BK4588","LU0310800965.SGD","LU1244550221.USD","TGT","BK4504","BK4155","BK4585","BVXV","LU0128525689.USD","LU1244550577.SGD","BK4007"],"gpt_icon":0},{"id":"2354989535","title":"M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2354989535","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2354989535?lang=en_us&edition=fundamental","pubTime":"2023-07-27 01:10","pubTimestamp":1690391400,"startTime":"0","endTime":"0","summary":"BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price. The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market. DICE Therapeutics is currently evaluating its lead drug candidate, DC-806, an oral IL-17 inhibitor, in a Phase II trial, with early-stage results from the Phase I study showing a near-44% reduction in Psoriasis Area and Severity Index. The report noted that the deal between Eli Lilly and DICE Therapeutics illustrates the potential valuation that BiondVax could receive with positive early-stage clinical results. Also, revenues from FDA-approved psoriasis drugs show the potential value of the company should its IL-17 NanoAb therapy eventually re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=21950339","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BVXV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biondvax.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.13925},{"month":2,"riseRate":0.25,"avgChangeRate":-0.05643},{"month":3,"riseRate":0.25,"avgChangeRate":0.004712},{"month":4,"riseRate":0.625,"avgChangeRate":0.111835},{"month":5,"riseRate":0.5,"avgChangeRate":0.049835},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.004257},{"month":7,"riseRate":0.555556,"avgChangeRate":0.047618},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.040335},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.064486},{"month":10,"riseRate":0.5,"avgChangeRate":-0.116698},{"month":11,"riseRate":0.5,"avgChangeRate":0.011329},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023745}],"exchange":"NASDAQ","name":"BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)","nameEN":"BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)(BVXV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)(BVXV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT),BVXV,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票老虎,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票老虎国际,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)行情,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票行情,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股价,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股市,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票价格,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票交易,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票购买,BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)(BVXV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BIONDVAX PHARMACEUTICALS SPON ADS EACH REP 400 ORD SHS(POST SPLT)(BVXV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction